ISSN- 0975-1491

Vol 7, Issue 2, 2015

Original Article

METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SERTRALINE AND DOXOFYLLINE IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC

B. VICTORIA RANI*1, C. PARTHIBAN1, M. SUDHAKAR2

¹Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy College of Pharmacy, Osmania University, Secunderabad 500014, India, ²Department of Pharmaceutics, Malla Reddy College of Pharmacy, Osmania University, Secunderabad 500014, India. Email: victoria_b189@yahoo.com

Received: 29 Sep 2014 Revised and Accepted: 20 Oct 2014

ABSTRACT

Objective: The aim of this work was to develop and validate a simple Reversed Phase - High Performance Liquid Chromatography method for the simultaneous estimation of Sertraline and Doxofylline in pharmaceutical dosage form.

Methods: The mobile phase consists of Phosphate buffer and Acetonitrile in the ratio of (30:70) with gradiant programming, Kromasil C_{18} (150×4.6 mm,5 μ) column used as stationary phase with a flow rate of 1 ml/min, injection volume 10 μ l and the run time was 7 min. Detection wavelength was at 234 nm by using Photo Diode Array detector.

Results: The retention times of Doxofylline and Sertraline retention were found to be 2.82 min and 3.93 min, respectively. The method was validated according to ICH guidelines. Validation parameters like accuracy, precision, linearity, range, limit of detection, limit of quantification and robustness all were within the limits. The linearity responses of Doxofylline and Sertraline were found to be in the concentration ranges of 100-600 ppm and 12.5-75 ppm. The percentage recovery for both drugs were found in the range of 99-100%. The LOD & LOQ values for Doxofylline were found to be 0.58 and 1.77µg/ml and Sertraline were found to be 0.27 and 0.82 µg/ml, respectively.

Conclusion: The results obtained are accurate and within the limits. Hence this method can be applicable for the estimation of Doxofylline and Sertraline in pharmaceutical dosage forms.

Keywords: Doxofylline and Sertraline, RP-HPLC, Validation.

INTRODUCTION

Doxofylline (also known as Doxophylline) is a xanthine derivative drug used in the treatment of asthma. It has antitussive and bronchodilator effects, and acts as a phosphodiesterase inhibitor. Chemically, Doxofylline is 7-(1, 3-dioxolan-2-methyl)-1,3-dimethyl purine-2,6-dione and the structure shown in figure-1. Sertraline is an antidepressant of the selective serotonin reuptake inhibitor. It is primarily prescribed for major depressive disorder in adult as well as obsessive-compulsive, panic and social anxiety disorders in both adults and children. Chemically, Sertraline is (1S, 4S)-4-(3,4-dichlorophenyl)-N-methyl - 1, 2, 3, 4 tetrahydronaphthalen-1-amine and the structure shown in fig. 2.

The literature survey reveals that the few HPLC method was developed and validated for the estimation of Doxofylline and Sertraline combination with other drugs. Lijuan He etal., Determined Sertraline in Human plasma by HPLC- Electrosray Ionisation Mass Spectrometry³. HR Joshi etal., estimated Doxofylline in tablets by Spectrophotometric and RP-HPLC⁴. Hence, it is necessary to develop a rapid,accurate and validated RP-HPLC method for the determination of Doxofylline and Sertraline from combined dosage form.

The developed method validated according to ICH guidelines. Since there is no reported method on simultaneous estimation of Doxofylline and Sertraline in combined tablet dosage forms. The main objective of this study was to develop and validate the assay method of Doxofylline and Sertraline in tablet dosage forms.

METHODS AND METHODS

Materials

Acetonitrile and water of HPLC grade were procured from Rankem lab ltd. Doxofylline and Sertraline standards were received as gift samples from Hetero Drugs Limited, Hyderabad, India. Ortho phosphoric acid A. R grade was purchased from E. Merck chemicals, Mumbai, India. Tablet DOXODER having combination of Doxofylline (400mg) and Sertraline (50mg) was used.

Instrumentation

The High performance liquid chromatography system consists of Waters 2695 with 2996 module Photo Diode Array detector equipped with a quaternary solvent delivery pump, automatic sample injector and column thermostat. The system was controlled by Empower 2 software and it is used for the analysis.

| S. No. | Name | Model |
|--------|------------------|-----------------------------------|
| 1 | Weighing Balance | Deniver |
| 2 | pH meter | Poloman |
| 3 | Sonicator | Ulta sonicator |
| 4 | HPLC | Water 2695 with 2996 PDA detector |

Method development

Standard stock solution preparation

Weigh and transfer 40mg of Doxofylline working standard and 5mg of Sertraline working standard into a 10 ml clean dry volumetric flask, add 7 ml of diluent, sonicated for 5 minutes and make up to the final volume with diluent.

Standard preparation

Transfer 1 ml from the above stock solution was taken into a 10 ml volumetric flask and dilute to volume with diluent. The standard solution consists of $400\mu g/ml$ of Doxofylline and $50\mu g/ml$ of Sertraline, respectively.

Sample preparation

Finely grind pre-weighed twenty tablets. Transfer grinded sample quantitatively equivalent to 40mg Doxofylline and 5mg of Sertraline into a 100 ml volumetric flask, add 70 ml of diluent, sonicate to

dissolve for 25 min, and the dilute to volume with diluent. Further filter the solution through filter paper. From the filtered solution 1 ml was pipetted out into a 10 ml volumetric flask and the volume made up to 10 ml with diluent then the solution consist of 400μ g/ml of Doxofylline and 50μ g/ml of Sertraline.

RESULTS AND DISCUSSION

System Suitability

The system suitability tests were conducted before performing the validation and the parameters were within the acceptance criteria like retention times of Doxofylline and Sertraline were 2.82 minutes and 3.93 minutes, respectively. The plate count was >2000, peak tailing was <2 and the %RSD of peak areas of standard svere 2.(Table 1), (fig. 3). Hence the proposed method was successfully applied to routine analysis without any problems.

Linearity

The linearity of Doxofylline and Sertraline were prepared in the range of 100-600 μ g/ml and 12.5-75 μ g/ml. These were represented by linear regression equation (Doxofylline) y=9208.7x+1630.4 (r=0.999), (Sertraline)y=7411.1x+606.64 (r=0.999). From the calibration curve the regression line for both drugs was linear (Table 2).

Precision

Injected standard preparation six times in same concentration in to the system. The precision of analytical method expresses closeness of agreement between a series of measurements obtained from multiple sampling of the homogenous under the prescribed conditions. Reproducibility and Repeatability for Doxofylline and Sertraline was shown in (Table 3). This indicated the method was highly precise.

Accuracy

The percentage recoveries for Doxofylline and Sertraline was found to be 98-120% and the %RSD for Doxfylline and Sertraline was found to be 0.34 and 0.63. The results of recovery studies was shown in (Table 4).

Robustness

Robustness data for Doxofylline and Sertraline by changing the parameters like flow rate, temperature and mobile phase ratio. It was shown in (Table 5).

Limit of detection and limit of quantification

The values of LOD and LOQ were calculated by using slope and Y-intercept. The LOD and LOQ values for Doxofylline was found to be 0.58 and 1.77μ g/ml and Sertraline was found to be 0.27 and 0.82 μ g/ml, respectively (Table 6).

Assay

The content of Doxofylline and Sertraline in the pharmaceutical dosage forms by using the developed method. The percentage purity of Doxofylline and Sertraline was found to be 99.85 % and 99.96% and %RSD values for both Doxofylline and Sertraline was within limit of ≤ 2 (Table 7).

Table 1: System suitability of Doxofylline and Sertraline

| S. No. | Doxofylli | ne | | | Sertraline | | | | |
|--------|-----------|----------|-----------------|-------------|------------|---------|-----------------|-------------|--|
| | Rt(min) | Area | USP Plate count | USP tailing | Rt (min) | Area | USP Plate count | USP tailing | |
| 1 | 2.803 | 3670119 | 8104 | 1.17 | 3.924 | 362952 | 7009 | 1.16 | |
| 2 | 2.807 | 3624766 | 8093 | 1.17 | 3.932 | 363964 | 7387 | 1.21 | |
| 3 | 2.808 | 3639058 | 8158 | 1.17 | 3.932 | 363266 | 7404 | 1.19 | |
| 4 | 2.818 | 3645506 | 8217 | 1.16 | 3.934 | 363258 | 7235 | 1.15 | |
| 5 | 2.823 | 3599764 | 8210 | 1.16 | 3.949 | 366194 | 7413 | 1.14 | |
| Mean | | 3635842 | | | | 363927 | | | |
| SD | | 25994.94 | | | | 1320.58 | | | |
| %RSD | | 0.71 | | | | 0.36 | | | |

SD=Standard deviation; RSD= Relative Standard deviation; Rt= Retention Time

Table 2: Linearity of Doxofylline and Sertraline

| Doxofylline | | Sertraline | | |
|-----------------------|---------|-----------------------|--------|--|
| Concentration (µg/ml) | Area | Concentration (µg/ml) | Area | |
| 100 | 959750 | 12.5 | 92562 | |
| 200 | 1805512 | 25 | 188687 | |
| 300 | 2765110 | 37.5 | 278100 | |
| 400 | 3624173 | 50 | 364097 | |
| 500 | 4700041 | 62.5 | 475030 | |
| 600 | 5494993 | 75 | 551182 | |

Table 3: Repeatability and Intermediate Precision of Doxofylline and Sertraline

| Drug | Repeatability | | Intermediate precisi | Intermediate precision | | |
|-------------|-------------------|----------|----------------------|------------------------|----------|------|
| | Peak area (N = 6) | Std. Dev | %RSD | Peak area (N = 6) | Std. Dev | %RSD |
| Doxofylline | 3634622 | 24031.21 | 0.66 | 3642856 | 21886.5 | 0.6 |
| Sertraline | 364706 | 2675.235 | 0.73 | 358767 | 5311.7 | 1.5 |

Doxofylline




Fig. 1: Structure of Doxofylline Sertralline




Fig. 2: Structure of Sertraline hydrochloride.

| Accuracy level (%) | Doxofylline Sertraline | | | | | | | |
|--------------------|------------------------|--------------------------|--------------------------|------------|---------------------------|--------------------------|--------------------------|------------|
| | Sample conc (µg/ml) | Added Conc (μg/ml) | Found Conc (µg/ml) | % Recovery | Sample Conc (µg/ml) | Added Conc (µg/ml) | Found Conc (µg/ml) | % Recovery |
| | 400 | 200 | 202.22 | 101.11 | 50 | 25 | 24.81 | 99.27 |
| 50% | 400 | 200 | 202.08 | 101.04 | 50 | 25 | 25.13 | 100.54 |
| | 400 | 200 | 201.46 | 100.73 | 50 | 25 | 25.26 | 101.07 |
| | 400 | 400 | 411.84 | 101.47 | 50 | 50 | 50.68 | 101.37 |
| 100% | 400 | 400 | 401.36 | 100.34 | 50 | 50 | 50.6 | 101.20 |
| | 400 | 400 | 401.12 | 100.28 | 50 | 50 | 50.04 | 100.09 |
| | 400 | 600 | 600.72 | 100.12 | 50 | 75 | 74.70 | 99.61 |
| 150% | 400 | 600 | 602.76 | 100.46 | 50 | 75 | 75.41 | 100.55 |
| | 400 | 600 | 599.82 | 99.97 | 50 | 75 | 75.60 | 100.81 |
| Mean | | | | 100.61 | | | | 100.50 |
| SD | | | | 0.5053 | | | | 0.7198 |
| %RSD | | | | 0.50 | | | | 0.71 |

Table 4: Accuracy of Doxofylline and Sertralline

Table 5: Robustness of Doxofylline and Sertraline


| Parameters | | Doxofylline | | | Sertraline | | |
|--------------|------------|-------------|----------|------|------------|--------|------|
| | | Mean Area | SD | %RSD | Mean Area | SD | %RSD |
| Flow rate | 0.9 ml/min | 3634346 | 183091.1 | 0.5 | 354211 | 4409.3 | 1.2 |
| | 1.0 ml/min | 3635842 | 25994.9 | 0.7 | 363927 | 1320.5 | 0.3 |
| | 1.1 ml/min | 3598463 | 14749.0 | 0.4 | 351526 | 4316.3 | 1.2 |
| Temperature | 25°C | 3524817 | 8670.3 | 0.2 | 346874 | 1168.8 | 0.3 |
| - | 30º C | 3635842 | 25994.9 | 0.7 | 363927 | 1320.5 | 0.3 |
| | 35°C | 3559288 | 4145.0 | 0.1 | 348047 | 3457.3 | 1.0 |
| Mobile phase | 29:71 | 3526011 | 10358.5 | 0.3 | 347571 | 182.4 | 0.1 |
| • | 30:70 | 3635842 | 25994.9 | 0.7 | 363927 | 1320.5 | 0.3 |
| | 31:69 | 3555832 | 25306.5 | 0.7 | 348190 | 3463.4 | 1.0 |


Table 6: Limit of Detection and Limit of Quantification

| S. No. | Parameters | Doxofylline | Sertralline |
|--------|------------|-------------|-------------|
| 1 | LOD | 0.58 | 0.27 |
| 2 | LOQ | 1.77 | 0.82 |

Table 7: Assay of Doxofylline and Sertraline

| | Label Claim | | Amount found | | |
|---------|-------------|-------------|-------------------|------------------|--|
| Doxoder | Doxofylline | Sertralline | Doxofylline | Sertralline | |
| | 400mg | 50mg | 399.42 ± 0.28 | 49.98 ± 0.44 | |








Fig. 4: Linearity graph of Doxofylline




Fig. 5: Linearity graph of Sertraline

CONCLUSION

The proposed analytical technique of RP-HPLC is simple, accurate and extensively used method for the simultaneous estimation of Doxofylline and Sertraline in pharmaceutical dosage forms has been developed. The method was validated as per ICH guidelines. Statistical analysis proves that method is repeatable, sensitive for the analysis of Doxofylline and Sertraline in pharmaceutical dosage forms.

CONFLICT OF INTERESTS

Declared None

REFERENCES

- 1. Giriraj, Shajan A. Simultaneous estimation and Method validation of Montelukast sodium and Doxofylline in Solid Dosage form by RP-HPLC. Int J Chem Pharm Sci 2011;2(1);31-6.
- K Venkateswarlu, RK Venisetty, NR Yellu, S Keshetty, MG Pai. Develpoment of HPTLC-UV absorption densitometry method for the analysis of alprazolam and sertraline in combination and its application in the evaluation of marketed preparations. J Chromatogr Sci 2007;45(2);537-9.
- 3. Lijuan He, Fang Feng, Jie Wu. Determination of sertraline in Human plasma by HPLC-Electrosray Ionisation mass

spectrometry and method validation. J Chromatogr Sci 2005;2(3);43.

- 4. HR Joshi, AH Patel, AD Captain. Spectrophotometric and RP-HPLC method for the determination of Doxofylline in pharmaceutical formulations. J Young Pharm 2010;2(3);289-96.
- 5. R Revathi, T Ethiraj, V Ganesan. HPLC method development for the simultaneous analysis of Doxofylline and Montelukast sodium in combined form. Pharm Methods 2011;2(4);223-8.
- G Samanthula, Krishnaveni Yadhiki, KV Surendranath. Stability indicating RP-HPLC method for the simultaneous estimation of Doxofylline and Terbutalinesulphate in Pharmaceutical formulations 2013;81(4);969-82.